{"version":"1.0","type":"link","title":"Favorable clinical impact of histological subtype with non-small cell carcinoma-not otherwise specified in patients with non-small cell lung cancer receiving immune checkpoint inhibitors.","author_name":"Hirano T 외","author_url":"https://prs-insight.online/author/Hirano%20T","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/96363","thumbnail_width":1200,"thumbnail_height":630}